RTS,S Malaria Vaccine — GlaxoSmithKline (2021)

After 30 years of development, Mosquirix became the first malaria vaccine recommended by the WHO for children in sub-Saharan Africa. While its 30% efficacy is modest, it prevents roughly 40,000 deaths annually when combined with other interventions — a milestone for a parasite that has killed billions throughout human history.